ArticleOncoimmunology2022

MUC1-C integrates type II interferon and chromatin remodeling pathways in immunosuppression of prostate cancer.

Masayuki Hagiwara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.